Clinical trials: Cerebrovascular Disorder
Dementia, Alzheimer Disease
All About Me: An Intervention to Ease the Transition to Long Term Care
This Phase I study will involve initial development and evaluation of an innovative cross-platform software app called All About Me (AAM), which will consist of Serious Digital Health Games (SDHGs) for PWD.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Dementia, Mixed
- Trial name
- AAM (NCT05516134)
- Testing
- SAFE at Home
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Hopeful Aging
MELAS, LHON
A Dose-escalating Clinical Trial With KH176
Mitochondrial Diseases are rare progressive, multi-system, often early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial…
- Conditions
- MELAS, LHON, Leigh Syndrome, Mitochondrial Disease
- Trial name
- NCT02544217
- Testing
- KH176
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Khondrion BV
Stroke
Evaluating Neuroprotection in Aneurysm Coiling Therapy
This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain damage.
- Trial name
- ENACT (NCT00728182)
- Testing
- NA-1
- Where
- 14 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- NoNO Inc.
Acute Ischemic Stroke (AIS)
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
- Trial name
- ARPEGGIO (NCT05585606)
- Testing
- scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Silver Creek Pharmaceuticals
Carotid Atherosclerosis, Carotid Artery Disease
ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"
1. To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) 2.
- Trial name
- NCT00180518
- Testing
- Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
- Volunteers
- 581 people
- Sponsor
- Abbott Medical Devices
Femoral Artery Stenosis, Iliac Artery Stenosis
Retrospective Study of the Uni-Graft® K DV Patch in the Clinical Routine
Uni-Graft® K DV Patch is marketed in Europe since 1999 for reconstructive interventions of the deep femoral, femoral and iliac artery and was also indicated for carotid interventions until 01/2020.
- Conditions
- Femoral Artery Stenosis, Iliac Artery Stenosis, Carotid Artery Stenosis
- Trial name
- RESTUGPA (NCT05117515)
- Testing
- Vascular reconstruction
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Aesculap AG
Intracranial Aneurysm
FRED and FRED JR Devices for Intracranial Aneurysm Treatment
A French, multicenter, prospective, observational, "real-world" assessment of the safety and efficacy of FRED and FRED Jr devices in the treatment of intracranial aneurysms
- Trial name
- NCT04315168
- Testing
- FRED and FRED JR
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Microvention-Terumo, Inc.
Ischemic Stroke
Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients
This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients
- Trial name
- NCT03823274
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 1,011 people
- Sponsor
- Yuhan Corporation
Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
- Trial name
- RESTORE (NCT06987643)
- Testing
- Neflamapimod
- Where
- 10 sites in Australia
- Volunteers
- 45 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease, Mild Cognitive Impairment
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia
- Trial name
- NCT01465360
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Exonhit
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.
- Trial name
- NCT00426803
- Testing
- activated recombinant human factor VII
- Where
- 15 sites in Australia, Austria and 13 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Patent Foramen Ovale, Cryptogenic Stroke
Encore PFO Closure Device - The PerFOrm Trial
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
- Trial name
- NCT05537753
- Testing
- Encore PFO closure device, FDA-approved PFO closure device
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Encore Medical Inc.
Atrial Fibrillation
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs…
- Trial name
- NCT03462446
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists (VKAs)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.
- Trial name
- NCT07396337
- Testing
- QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group)
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Ischemic Stroke
Glyburide Advantage in Malignant Edema and Stroke Pilot
The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard…
- Trial name
- GAMES-PILOT (NCT01268683)
- Testing
- Glyburide for Injection
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Mild Cognitive Impairment, Alzheimer Disease
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Alzheimer Dementia, Dementia, Vascular
- Trial name
- NCT03538522
- Testing
- N-831(Traneurocin) 10 mg QD, NA-831 (Traneurocin) 20 mg QD, NA-831 (Traneurocin) 40 mg QD
- Where
- 2 sites in New Zealand
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Cerebral Infarction
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects.
- Trial name
- NCT02562183
- Testing
- kallikrein
- Where
- 7 sites in China
- Volunteers
- 2,186 people
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
Dementia Associated With Cerebrovascular Disease
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
The primary objectives are to confirm that donepezil hydrochloride has superior efficacy compared with placebo in improving cognitive function, as measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog)…
- Trial name
- NCT02660983
- Testing
- Donepezil hydrochloride
- Where
- 31 sites in South Korea
- Volunteers
- 302 people
- Sponsor
- Eisai Co., Ltd.
Carotid Artery Diseases, Stroke
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with…
- Trial name
- WISE (NCT01783639)
- Testing
- Carotid Artery Stent
- Where
- 10 sites in Belgium, Germany and 1 more
- Volunteers
- 120 people
- Sponsor
- Gardia Medical
Heart Attack, Stroke
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
Cardiovascular diseases (CVD) are currently the leading cause of death in industrialized countries and are expected to become the leading cause of death in emerging countries by 20201.
- Conditions
- Heart Attack, Stroke, Cardiovascular Death
- Trial name
- NCT03654157
- Where
- 27 sites in Russia
- Volunteers
- 1,576 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.